Virax Biolabs Group Ltd (VRAX) Accounts Payables (2021 - 2025)

Virax Biolabs (VRAX) has 5 years of Accounts Payables data on file, last reported at $56093.0 in Q1 2025.

• In Q1 2025, Accounts Payables rose 22.93% year-over-year to $56093.0; the TTM figure through Mar 2025 stood at $56093.0 (up 22.93% YoY), while the FY2025 annual figure was $56093.0, up 22.93% from the prior year.
• Accounts Payables climbed to $56093.0 in Q1 2025, from $45631.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $846474.0 in Q1 2022 and bottomed at $45631.0 in Q1 2024.
• A 5-year average of $265050.2 and a median of $159908.0 in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 289.82% — and 2023, when it plunged 81.11%.
• Year by year, Accounts Payables stood at $217145.0 in 2021, then soared by 289.82% to $846474.0 in 2022, then plunged by 81.11% to $159908.0 in 2023, then tumbled by 71.46% to $45631.0 in 2024, then gained by 22.93% to $56093.0 in 2025.
• The last three Accounts Payables figures came in at $56093.0 (Q1 2025), $45631.0 (Q1 2024), and $159908.0 (Q1 2023), per Business Quant data.

Peer Comparison